While we all understand that Covid-19 is a virus, data shows that antibiotics are being utilized at a higher rate and possibly compounding the already growing issue of drug-resistant bacteria. On this front, our fight relies on continued R&D in the pharma space, and research has suffered as a result of the pandemic. This consequence paints a challenging picture in the battle against resistant bacteria that will require a global action plan. The WHO and the ARM Action Fund have provided insightful information and proposed solutions that will affect the healthcare, R&D, and pharmaceutical industries.
The WHO global action plan seeks to improve awareness of the issue, bolster research, improve sanitization, cut back excessive use of antimicrobial medicines in human and animal health and invest in new medicines to act against the superbugs.